Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IPCIQ's EV-to-OCF is not ranked *
in the Biotechnology industry.
Industry Median: -3.72 * Ranked among companies with meaningful EV-to-OCF only.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
IntelliPharmaCeutics International (OTCPK:IPCIQ) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
IntelliPharmaCeutics International's PE Ratio (TTM) for today is calculated as:
IntelliPharmaCeutics International's share price for today is $0.15.
IntelliPharmaCeutics International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Aug. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.092.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
IntelliPharmaCeutics International EV-to-OCF Related Terms
IntelliPharmaCeutics International EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IntelliPharmaCeutics International EV-to-OCF Chart
For the Biotechnology subindustry, IntelliPharmaCeutics International's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IntelliPharmaCeutics International EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where IntelliPharmaCeutics International's EV-to-OCF falls into.
IntelliPharmaCeutics International's current Enterprise Value is $0.00 Mil.
IntelliPharmaCeutics International's Cash Flow from Operations for the trailing twelve months (TTM) ended in Aug. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IntelliPharmaCeutics International (IPCIQ) has a EV-to-OCF of 0.00 as of Aug. 30, 2026.
Is IntelliPharmaCeutics International's EV-to-OCF too high?
IntelliPharmaCeutics International's current EV-to-OCF is 0.00. Overall, IntelliPharmaCeutics International has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does IntelliPharmaCeutics International's EV-to-OCF compare to CHRO and KTTA?
IntelliPharmaCeutics International's EV-to-OCF of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. IntelliPharmaCeutics International's current EV-to-OCF is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IntelliPharmaCeutics International stock overvalued right now?
IntelliPharmaCeutics International (IPCIQ) has a current EV-to-OCF of 0.00. The current EV-to-OCF is 0.00. IntelliPharmaCeutics International's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For IntelliPharmaCeutics International (IPCIQ), the current EV-to-OCF is 0.00 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
IntelliPharmaCeutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company's patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline.
16GF Score
Get the complete analysis for IPCIQ
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPCIQ has been successfully added to your 
